首页 > 市场调查报告书 > 製药

甲氨蝶呤药物市场：按治疗类型、给药途径、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2030 年

市场调查报告书

商品编码

1149827

甲氨蝶呤药物市场：按治疗类型、给药途径、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2030 年

Methotrexate Drugs Market, by Treatment Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年10月12日 | 出版商:

Coherent Market Insights | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

简介目录

甲氨蝶呤是一种缓解疾病的抗风湿药 (DMARD)。它用于抑制某些疾病患者的免疫系统活动。通常，免疫系统通过产生炎症来抵抗感染来保护身体免受感染。炎症会导致肿胀、发热、发红和疼痛。甲氨蝶呤有片剂、液体和注射剂形式。甲氨蝶呤片剂有两种规格，2.5 毫克和 10 毫克。甲氨蝶呤抑制体内某些细胞的生长，尤其是快速生长的细胞，如癌细胞、骨髓细胞和皮肤细胞。

市场动态

市场上的主要参与者都在从事研发活动以开发甲氨蝶呤药物，预计这将在预测期内推动全球甲氨蝶呤药物市场的增长。例如，2019 年 6 月，辉瑞公司宣布了 ORAL Shift 的阳性结果，这是一项针对中度至重度活动性类风湿性关节炎 (RA) 成年患者的 3b/4 期试验。在为期 24 週的开放标籤磨合期后，随机分配使用 XELJANZ（託法替尼）缓释（XR）11 mg 每天一次（QD）加甲氨蝶呤（MTX）达到低疾病活动度（LDA）的患者以评估疗效与 XELJANZ XR 继续使用 MTX 相比，XELJANZ XR 11mg QD 单一疗法在 MTX 停药后的安全性和安全性。

组织提高认识的努力、关节炎患病率的增加以及产品发布等因素正在推动全球甲氨蝶呤医药市场的增长。例如，2018 年 5 月，Hikma Pharmaceuticals PLC.宣布在预计市场参与者的这些努力将在预测期内推动全球甲氨蝶呤医药市场的增长。此外，针对关节炎和癌症的管线中还有数种潜在药物，有望推动全球甲氨蝶呤药物市场的增长。

这项研究的主要特点

本报告对全球甲氨蝶呤医药市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。
解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
根据公司亮点、产品组合、主要亮点、经营业绩和战略等参数，对全球甲氨蝶呤医药市场的主要参与者进行了概况分析。
本研究涵盖的主要公司包括 LEO Pharma A/S、Bristol Myers Squibb、Nordic Pharma、Eli Lilly and Company、Horizo□□n Therapeutics plc.、Cumberland Pharmaceuticals Inc.、Azurity Pharmaceuticals, Inc.、Pfizer Inc.、 Hikma Pharmaceuticals PLC.和 Onco Therapies Limited (Strides Arcolab Limited)。
这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
《全球甲氨蝶呤医药市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以通过用于分析全球甲氨蝶呤药物市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

报告内容
- 市场定义和范围
执行摘要
- 市场概况：按治疗类型分类
- 按给药途径划分的市场概况
- 市场概况：按销售渠道
- 市场概况：按地区
连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

市场动态
- 司机
- 约束因素
- 市场机会
监管情景
新药上市
主要亮点
研发合作、併购
害虫分析
管道分析
流行病学

第 4 章全球甲氨蝶呤药物市场：冠状病毒 (COVID-19) 大流行的影响

总体影响
政府举措
COVID-19 对市场的影响

第 5 章全球甲氨蝶呤药物市场：按治疗类型分类，2017-2030

银屑病
类风湿性关节炎
癌症

第 6 章全球甲氨蝶呤药物市场：按给药途径，2017-2030

口语
注射

第 7 章。甲氨蝶呤药物的全球市场：按分销渠道，2017-2030

医院药房
零售药房
在线药店

第 8 章。全球甲氨蝶呤药物市场：按地区划分，2017-2030

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
意大利
法国
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
东盟
澳大利亚
韩国
其他亚太地区
中东
海湾合作委员会
以色列
其他中东地区
非洲
北非
中非
南非

第9章竞争格局

热图分析
公司简介
- LEO Pharma A/S
- Bristol Myers Squibb
- Nordic Pharma
- Eli Lilly and Company
- Horizon Therapeutics plc.
- Cumberland Pharmaceuticals Inc.
- Azurity Pharmaceuticals, Inc.
- Pfizer Inc.
- Hikma Pharmaceuticals PLC.
- Onco Therapies Limited（Strides Arcolab Limited）

第 10 章

参考资料
调查方法

简介目录

Product Code: CMI5276

Methotrexate is a type of disease-modifying anti-rheumatic drug (DMARD). It is used to reduce the activity of the immune system for people who have certain conditions. The immune system normally protects the body from infections by causing inflammation to fight them. Inflammation can cause swelling, heat, redness and pain. Methotrexate is available in tablet, liquid or injection form. Methotrexate tablets come in two strengths: 2.5 mg and 10 mg. Methotrexate interferes with the growth of certain cells of the body, especially cells that reproduce quickly, such as cancer cells, bone marrow cells, and skin cells.

Market Dynamics

Key players in market are involved in research and development activities to develop Methotrexate drugs which is expected to drive the growth of global methotrexate drugs market over the forecast period. For instance, in June 2019, Pfizer Inc., announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA). Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of XELJANZ XR 11 mg QD as monotherapy after MTX withdrawal compared with XELJANZ XR with continued MTX.

Factors such as awareness initiatives by organizations, increasing prevalence of Arthritis, and product launches are driving the global methotrexate drugs market growth. For instance, in May 2018, Hikma Pharmaceuticals PLC., announced that it is wholly owned U.S. subsidiary West-Ward Pharmaceuticals Corp., has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection, USP 50mg/2mL, 2 mL vials. Such initiatives by market players are expected to boost the global methotrexate drugs market growth over the forecast period. Moreover, pipeline for Arthtitis, cancers has several potential medications, which is expected to drive global methotrexate drugs market growth.

Key features of the study:

This report provides an in-depth analysis of the global methotrexate drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global methotrexate drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include LEO Pharma A/S, Bristol Myers Squibb, Nordic Pharma, Eli Lilly and Company, Horizon Therapeutics plc., Cumberland Pharmaceuticals Inc., Azurity Pharmaceuticals, Inc., Pfizer Inc., Hikma Pharmaceuticals PLC., and Onco Therapies Limited (Strides Arcolab Limited).
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global methotrexate drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global methotrexate drugs market.

Detailed Segmentation:

Global Methotrexate Drugs Market, By Treatment Type:
- Psoriasis
- Rheumatoid Arthritis
- Cancer
Global Methotrexate Drugs Market, By Route of Administration:
- Oral
- Injection
Global Methotrexate Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Methotrexate Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- LEO Pharma A/S*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bristol Myers Squibb
- Nordic Pharma
- Eli Lilly and Company
- Horizon Therapeutics plc.
- Cumberland Pharmaceuticals Inc.
- Azurity Pharmaceuticals, Inc.
- Pfizer Inc.
- Hikma Pharmaceuticals PLC.
- Onco Therapies Limited (Strides Arcolab Limited)

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
New Drug Launch
Key Highlights
Research and Development Collaboration, Mergers, and Acquisitions
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Methotrexate Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Methotrexate Drugs Market, By Treatment Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Psoriasis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Rheumatoid Arthritis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Methotrexate Drugs Market, By Route Of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Injection
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Methotrexate Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Methotrexate Drugs Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa